Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NOX 100

Drug Profile

NOX 100

Alternative Names: Norathiol; NOX-100

Latest Information Update: 03 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medinox
  • Developer Medinox; Orient Europharma
  • Class Free radicals; Hexanols; Small molecules; Thiocarbamates; Vascular disorder therapies
  • Mechanism of Action Nitric oxide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Intradialytic hypotension; Septic shock
  • Discontinued Acute lung injury; Adult respiratory distress syndrome; Transplant rejection

Most Recent Events

  • 03 Oct 2019 Chemical structure information added
  • 01 Jul 2015 Medinox and Orient Europharma completes a phase II trial in Intradialytic hypotension in Taiwan (IV) (NCT01672008)
  • 08 Jun 2015 Phase-I/II clinical development is ongoing for septic shock, and phase-II development is ongoing for intradialytic hypotension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top